Propranolol corrects the abnormal catecholamine response to light during migraine.
The catecholamine (CA) response to light before and after propranolol therapy was studied in 25 migrainous subjects. Before therapy an abnormal CA response to light consisting of a rise in epinephrine excretion and a depression in norepinephrine (NE) excretion was noticed in migrainous patients. After propranolol administration (60 mg daily for 10 days) the post-photic augmentation in epinephrine excretion and the post-photic depression in NE excretion no longer occurred. As epinephrine discharge may be pathogenetic for migraine attack, the favorable effect of propranolol in migraine therapy could be due to its ability to prevent the epinephrine release induced by light or other stimuli.
Stoica
E
E
Institute of Neurology and Psychiatry, Bucharest, Rumania.
Enulescu
O
O
D000328:Adult; D004837:Epinephrine / Q000652:urine*; D005260:Female; D006801:Humans; D008297:Male; D008881:Migraine Disorders / Q000188:drug therapy / Q000503:physiopathology* / Q000652:urine; D009638:Norepinephrine / Q000652:urine*; D010775:Photic Stimulation; D011433:Propranolol / Q000627:therapeutic use*
D011433:Propranolol; D009638:Norepinephrine; D004837:Epinephrine